Edesa Biotech has shared data from its truncated phase 3 respiratory failure trial, linking the anti-TLR4 antibody to ...

Town leaders are looking to begin the second phase of development of McCord Square soon as the new town center comes to life.

At least five Wall Street firms have downgraded their ratings on Intellia Therapeutics (NASDAQ:NTLA) in the wake of the ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

In the randomized, double-blind, pediatric and adolescent, placebo-controlled study, CTx-1301 delivered rapid onset of effect and sustained efficacy through the evening hours. Safety and tolerability ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ('Reviva” or the 'Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of ...

Merck (MRK) and Eisai (ESAIY) announced that the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG, Merck’s first-in-class ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Intellia Therapeutics recently announced it has paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z for transthyretin amyloidosis following a serious ...

The City of Cambridge quietly paid The Equity Process — the firm that led the district’s controversial superintendent search ...

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns ...

Neurocrine Biosciences (NASDAQ: NBIX) delivered a decisive earnings beat in Q3, posting adjusted EPS of $2.17 against ...